GLP-1s for Diabetes: Pros and Cons
GLP-1 drugs are also a potent glucose-lowering therapy. GLP-1s work by triggering the pancreas to release more insulin, slowing digestion, and reducing hunger. The typical result is improved metabolic health and weight loss, both of which directly improve diabetes management.
GLP-1s: The Pros
Unlike insulin, which has mixed benefits for people with diabetes, GLP-1 drugs offer benefits that seem to be comprehensively positive:
- Lower blood sugar
- Weight loss
- Cardiovascular and kidney benefits
- Improved insulin resistance
“Insulin remains one of the most potent glucose-lowering therapies we have, but it’s no longer accurate to imply that insulin is always a clearly superior choice to GLP-1–based therapy for lowering A1C in type 2 diabetes,” says Hatipoglu.
GLP-1 drugs are also much easier to use than insulin. They carry a low risk of hypoglycemia despite their ability to prevent glucose spikes, and administration is straightforward, typically with one injection per week. With insulin, many people must take multiple injections every day, varying doses depending on their meals and activity level.
For a person with type 2 diabetes who doesn’t need urgent treatment for high blood sugar, especially if they have obesity, heart disease, high cardiovascular risk, or kidney disease, a GLP-1 is often the more attractive first injectable option, says Hatipoglu.
“In those patients, the question is no longer which lowers sugar more but rather which improves glycemia while also helping weight, hypoglycemia risk, cardiovascular risk, and possibly kidney outcomes,” says Hatipoglu. “On that broader scorecard, GLP-1s often come out ahead.”
GLP-1s: The Cons
GLP-1 drugs aren’t entirely without their own risks.
Perhaps more importantly, for some people with type 2 diabetes, GLP-1 drugs just aren’t effective enough to discontinue insulin use.
“When the pancreas can no longer produce enough insulin in very advanced diabetes, GLP-1 drugs cannot replace insulin,” says Hatipoglu. GLP-1 medications work by stimulating insulin-producing cells, but if a person with advanced diabetes has too few of those cells, it won’t make a meaningful difference.
Read the full article here
